- Trial phase
- Preclinical
- Time to market
- Years away, if ever. The program is still in preclinical (animal) testing, with a pilot efficacy study just initiating. Veterinary regulatory approval (USDA or equivalent) would follow successful studies, but no timeline has been disclosed.
- Why 1/10
- PCRX-1001 is a preclinical veterinary candidate with no scheduled PDUFA, pivotal readout, or any dated binary catalyst in the next 12 months. The stock's value is determined by Viatris's pending $36.50/share acquisition, not by this early-stage program. Impact score is 1: preclinical, minor program, no catalyst.
PCRX-1001 has no dated binary catalyst. The stock is trading at $36.39, essentially at Viatris's $36.50/share tender offer price, so the acquisition outcome (expected to close by end of 2026) is the only material catalyst for PCRX shares. PCRX-1001's next milestone would be preclinical efficacy data or a potential out-licensing deal, neither of which is dated or would move the stock given the pending acquisition.
Price Chart
Executive Summary
PCRX-1001 is a preclinical high-capacity adenovirus (HCAd) gene therapy candidate for canine osteoarthritis (OA), developed by Pacira BioSciences (NASDAQ: PCRX). It is one of three preclinical HCAd programs (alongside PCRX-1002 for dry eye and PCRX-1003 for degenerative disc disease) that the company has described as having significant out-licensing potential. Pacira completed a pilot safety study and is initiating a pilot efficacy study for PCRX-1001. However, the program is very early stage and a minor part of Pacira's pipeline, which is dominated by commercial products EXPAREL and Zilretta and the Phase 2 gene therapy PCRX-201. Furthermore, on October 8, 2026, Viatris agreed to acquire Pacira for $36.50 per share in cash, making PCRX-1001's standalone prospects largely irrelevant to the stock's near-term value.
How It Works
PCRX-1001 is a gene therapy that uses a modified, non-replicating virus (high-capacity adenovirus or HCAd) to deliver genetic material into cells. It is designed to treat osteoarthritis in dogs by targeting the underlying inflammatory processes that cause joint pain and cartilage breakdown. The therapy is administered locally into the joint.
Trial Status
PCRX-1001 is in preclinical development for canine osteoarthritis. Pacira completed a pilot safety study and its pilot efficacy study is now initiating, as disclosed in the Q2 2026 10-Q filing. The company has described the program as having significant out-licensing potential.
The Two-Sided Case
Upcoming Catalysts
- Preclinical efficacy data (no date disclosed)
- Potential out-licensing deal (no date disclosed)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Pacira BioSciences, Inc. SC 14D-9 PCRX ·Originating report